Products
NRF2, NFE2L2 antibody
- Product Name
- NRF2, NFE2L2 antibody
- Catalogue No.
- FNab05855
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- nuclear factor(erythroid-derived 2)-like 2
- Alternative Names
- HEBP1 antibody, NF E2 related factor 2 antibody, NFE2 related factor 2 antibody, NFE2L2 antibody, NRF2 antibody
- UniProt ID
- Q16236
- Observed MW
- 70-100 kDa
Application
- Tested Applications
- ELISA, IP, WB, IHC, FC
- Recommended dilution
- WB: 1:200-1:2000; IP: 1:200-1:1000; IHC: 1:50-1:500
Validated Images
DMSO treated HeLa cells were subjected to SDS PAGE followed by western blot with FNab05855(NRF2, NFE2L2 Antibody) at dilution of 1:600
IP Result of anti-NRF2, NFE2L2 (IP: FNab05855, 3ug; Detection: FNab05855 1:300) with mouse kidney tissue lysate 4000ug.
Immunohistochemistry of paraffin-embedded human ovary tumor tissue slide using FNab05855(NRF2, NFE2L2 Antibody) at dilution of 1:200 heat mediated antigen retrieved with Tris-EDTA buffer(pH9).
- Background
- NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response(ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress(PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC.
